Delcath Systems, Inc.

Delcath Systems, Inc.

DCTHNYSE / NASDAQHealthcareSmall cap

$18.79-$0.45 (-2.3%)

Last close · Data as of Nov 20, 2026

Market cap
$372.5M
P/E
138.0x
EV / EBITDA
327.0x
Revenue
$85.2M
Net margin
3.2%
ROCE
0.6%

+129.4% over the last year

Delcath Systems, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+27.3%
3M
+12.2%
6M
+67.3%
1Y
+129.4%
5Y
+97.8%

52-week range

Day change -$0.45 (-2.3%) from $19 to $19 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in DCTH, bought on each weekday since 2021.

News & filings

What Delcath Systems filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -38.4% to 2.4% between fiscal 2024 and fiscal 2025.

Concerns (1)

  • Operating profit was 0.5 times interest costs.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Read moreShow less

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Sector
Healthcare
Shares outstanding
33.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$372.5M
P/E
138.0x
P/B
3.3x
EV / EBITDA
327.0x
EV / Sales
3.9x
P/S
4.4x
52-week high
$21.77
52-week low
$8.19

Profitability

Operating margin
0.8%
Net margin
3.2%
EBITDA margin
1.2%
ROE
2.4%
ROCE
0.6%
ROIC
0.7%
ROA
2.2%
Asset turnover
0.69

Growth

Revenue
$85.2M
Revenue growth, 1Y
129.1%
Revenue CAGR, 3Y
215.3%
Net profit growth, 1Y
-110.2%
Free cash flow
$21.0M

Solvency

Current ratio
10.92
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
8.34
Cash / Market cap
11.7%

Where the revenue went

Of every $100 of FY2025 revenue, $3 was left as net income.

Delcath Systems, Inc. income statement flow, FY2025
Delcath Systems, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$11.8M
RevenueGross profit$73.4M
Gross profitOperating expenses$72.8M
Gross profitOperating income$660.0k
Operating incomePretax income$660.0k
Interest and other incomePretax income$2.8M
Pretax incomeTax and other$810.0k
Pretax incomeNet income$2.7M

Revenue and net profit

Revenue grew 129.1% in FY2025; net profit is the dashed line.

Delcath Systems, Inc. revenue and net profit by fiscal year
Delcath Systems, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$2.7M-$36.5M
FY2023$2.1M-$47.7M
FY2024$37.2M-$26.4M
FY2025$85.2M$2.7M

Cash flows

FY2025: $22.5M from operations, $21.0M free after investment (dashed).

Delcath Systems, Inc. operating and free cash flow by fiscal year
Delcath Systems, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$24.9M-$25.2M
FY2023-$31.3M-$31.3M
FY2024-$18.7M-$19.2M
FY2025$22.5M$21.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$85.2M+129.1%1Y
EBITDA
$1.0M
Net profit
$2.7M
Cash from operations
$22.5M
Free cash flow
$21.0M
Revenue CAGR, 3Y
215.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$85.2M$1.0M$2.7M$21.0M2.4%+129.1%-110.2%

Monthly returns

Month-by-month returns of DCTH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$123.6M
Liabilities$12.4M
Equity$111.2M
Paid-in capital$639.1M
Retained earnings-$528.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; DCTH highlighted.

P/E against peers

DCTH trades at 138.0x earnings against a peer median of -5.8x.

  1. Delcath Systems, Inc. (this company)138.0x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Compass Therapeutics, Inc., Benitec Biopharma Inc., Lexeo Therapeutics, Inc., Perspective Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Delcath Systems, Inc.DCTHthis company$372.5M138.0x3.3x2.4%327.0x
OmniAb, Inc.OABI$385.6M-6.0x1.4x-24.3%-8.1x
Compass Therapeutics, Inc.CMPX$383.6M-5.8x1.9x-33.8%-5.1x
Benitec Biopharma Inc.BNTC$379.6M-10.0x3.9x-39.0%-6.8x
Viemed Healthcare, Inc.VMD$377.2M25.3x2.7x10.6%7.4x
CapsoVision, Inc.CV$376.7M-14.9x28.4x-190.9%-14.7x
Vanda Pharmaceuticals Inc.VNDA$375.8M—1.1x-67.4%—
Lexeo Therapeutics, Inc.LXEO$375.3M-3.8x1.5x-40.5%-3.3x
Perspective Therapeutics, Inc.CATX$370.7M-3.6x1.8x-49.8%-3.4x
Peer median—-5.8x1.9x-39.7%-5.1x

Year-to-date ROI

DCTH since 1 January, against earlier years.

Historical volatility

DCTH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Delcath Systems, Inc. operating margin by fiscal year
Delcath Systems, Inc. operating margin by fiscal year
DateOperating margin
FY2022-1244.5%
FY2023-1853.4%
FY2024-33.4%
FY20250.8%
LineFY2025
Cost of revenueCost Of Revenue$11.8M
Gross profitGross Profit$73.4M
Operating expensesOperating Expense$72.8M
Research and developmentResearch And Development$29.3M
Selling, general and administrativeSelling General And Administration$43.5M
Total expensesTotal Expenses$84.6M
Pretax incomePretax Income$3.5M

Learn while you research

Academy chapters picked for Delcath Systems, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 138.0, learn when high multiples are justified.6 min read
  3. 03 Growth Investing129% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →